MSI-78: Started second Phase III trial of a 1 percent concentration of MSI-78 to demonstrate equivalence to oral ofloxacin. The number of patients wasn't disclo

Magainin Pharmaceuticals Inc. (MAGN), Plymouth Meeting, Penn. Product: MSI-78 Indication: Infected diabetic foot ulcers Status: Started second Phase III trial of a 1 percent concentration of MSI-78 to...